Two studies (discovery and validation) Discovery AD: aMCI: Healthy controls: Validation AD: aMCI: Healthy controls:
Two studies (discovery and validation) Discovery Mean age AD: 77.09 aMCI: 70.4 Healthy controls: 69.94 Validation Mean age AD: 70.11 aMCI: 71.5 Healthy controls: 71.4
Two studies (round one and round two) Round one AD: aMCI: n=55 Healthy controls: Round two AD: FTD: Healthy older controls: Neurological patients (other than dementia): Young healthy controls:
Two studies (round one and round two) Round one Median age (IQR) AD: 80 (9) aMCI: 78 (14) Healthy controls: 73 (6) Round two Median age (IQR) AD: 80 (8) FTD: 71.5 (10) Healthy older controls: 72 (7) Neurological patients (other than dementia): 55 (11) Young healthy controls: 32 (22)
Two studies (round one and round two) Round one Male/female AD: 24/22 aMCI: 23/32 Healthy controls: 15/32 Round two Male/female AD: 17/24 FTD: 11/5 Healthy older controls: 14/30 Neurological patients (other than dementia): 5/7 Young healthy controls: 31/45
Two studies (round one and round two) Round one ↑ p-tau/t-tau at phosphorylation site: S396, S404, and the combination of S400, T403, and T404, value < 0.05 Round two ↑ median p-tau/t-tau at phosphorylation site: S396, value AD/healthy older controls < 0.05 Sensitivity S396: 73% Specificity S396: 50% Sensitivity S404: 83% Specificity S404: 30%
Two studies (discovery and validation) Discovery ↓ lactoferrin, value AD/healthy controls < 0.001, value aMCI/healthy controls < 0.001 Validation Sensitivity: 100%, specificity: 100% Correlation with CSF Aβ42: value < 0.001 Correlation with CSF t-tau: value < 0.001 Correlation with MMSE in AD and aMCI: value < 0.001
Aβ42: ↑ concentration in mild and moderate AD value mild AD = 0.043 value AD/healthy control < 0.05 Sensitivity: 16% Specificity: 93% Interaction with age: value = 0.016 Interaction with gender: value = 0.002 Aβ40: ↑ concentration in AD and PD